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ABSTRACT
The objective of this study was to estimate the direct costs associated with the diagnosis 
and treatment of neurocysticercosis (NCC) during pre-hospitalization, hospitalization, and post-
hospitalization periods for 108 NCC patients treated at the Instituto Nacional de Neurologia 
y Neurocirugia (INNN) in Mexico City, Mexico. Information on clinical manifestations, 
diagnostic tests, hospitalizations, surgical procedures, prescription medication, and other 
treatments was collected via medical chart reviews. Uncertain values for costs and frequency of 
treatments were imputed using bootstrap techniques. The average per-patient pre-hospitalization 
and hospitalization costs were US$ 257 (95% CI: 185 – 329) and US$ 2,576 (95% CI: 2,244 
– 2,908), respectively. Post-hospitalization costs tended to decrease over time, with estimates 
for the first five years post-hospitalization of US$ 475 (95% CI: 423 – 527), US$ 228 (95% CI: 
167 – 288), US$ 157 (95% CI: 111 – 202), US$ 150 (95% CI: 106 – 204), and US$ 91 (95% 
CI: 27 – 154), respectively. NCC results in a significant economic burden for patients requiring 
hospitalization, with this burden continuing years post-hospitalization.
KEYWORDS: Cost. Hospitalization. Neurocysticercosis.
INTRODUCTION
Neurocysticercosis (NCC) is caused by the larval stage of Taenia solium. The 
disease occurs when a human inadvertently ingests parasite eggs that have been 
shed in the feces of a person infected with taeniasis, with the eggs developing into 
larvae in the central nervous system. NCC is predominantly found and considered 
endemic in Latin American, Asian, and African countries where pigs are raised 
using traditional methods, veterinary meat inspection is insufficient, and sanitation 
is poor1-3. It has also been increasingly diagnosed in higher income areas such as the 
United States, Western Europe, and Canada due to immigrants from endemic areas 
who may have taeniasis or cysticercosis4,5. In Mexico and other Latin American 
countries, NCC is considered one of the leading causes of epilepsy6,7.
In humans, NCC is associated with numerous clinical manifestations, including 
epilepsy, hydrocephalus, focal deficits, severe chronic headaches, increased 
intracranial pressure, dementia, vasculitis, and stroke8. These NCC-associated 
clinical manifestations have been shown to affect the patients’ quality of life leading 
to poorer physical and mental health and important economic consequences9-12. 
Studies conducted in India, Peru, and Mexico have estimated the average direct and 
indirect costs per NCC patient under care9,13,14, while two studies from the United 
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States and one from Chile evaluated hospital-associated 
charges for NCC patients15-17. However, the per-patient 
costs associated with pre-hospitalization, hospitalization, 
and post-hospitalization for NCC have not been evaluated.
Period-specific cost estimates will be crucial for policy 
makers to comprehensively understand the true economic 
impact of the disease in order to prioritize and allocate 
resources. Therefore, this study was conducted to better 
define direct costs associated with pre-hospitalization, 
hospitalization, and post-hospitalization for NCC patients 
seeking care at a referral hospital in Mexico City, Mexico, 
taking into consideration costs to the healthcare system 
as well as medication paid for by the patients themselves. 
MATERIALS AND METHODS
Study location
This study was conducted in a referral hospital for adult 
neurological cases in Mexico City, Mexico: the Instituto 
Nacional de Neurologia y Neurocirugia (INNN). The INNN 
only accepts patients who do not have medical insurance 
coverage through their employment. NCC patients with 
employer-provided medical insurance are seen at a different 
referral hospital in Mexico City and are, therefore, not 
represented in the current study.
Definition and study populations
NCC was defined based on the presence of compatible 
cerebral lesions on a computed tomography (CT) scan, 
magnetic resonance imaging (MRI), or both18. Outpatients 
diagnosed with NCC and with a clinical appointment at 
the INNN between July 17 and December 7, 2007 were 
eligible to participate. Eligible patients were identified using 
outpatient appointment books, which allowed a research 
assistant to explain the study and ask for the patient’s 
consent at the time of the appointment. NCC outpatients 
were sequentially invited to participate until at least 100 
patients were enrolled. The medical charts of consenting 
patients were reviewed by a trained member of the research 
team (i.e., a Mexican intern, resident, or social worker). 
Only patients alive at the time of recruitment and who were 
hospitalized for the treatment of NCC between January 
2002 and August 2007 were included in this study. 
Data collection
Four forms were used to gather information on 
presenting clinical manifestations, diagnostic tests 
performed, number of days of hospitalization, surgical 
procedures, and treatments received by the patients, 
including prescription medications. An intake form was 
used to record information on the NCC-associated clinical 
manifestation(s) that caused the patient to be referred to the 
hospital. A diagnostic and treatment form was used to record 
information on techniques employed for the confirmation 
of NCC and the medications and procedures used for its 
treatment. Inpatient and outpatient forms were used to 
record information on the number of times the patients 
were hospitalized or had an outpatient appointment for the 
treatment and management of NCC.
Direct costs associated with pre-hospitalization, 
hospitalization, and post-hospitalization of NCC 
patients
Diagnosis and treatment-related costs were 
calculated for the pre-hospitalization, hospitalization, 
and post-hospitalization periods, beginning with the 
first NCC-associated visit to the INNN. The frequency 
of appointments with various healthcare providers 
(neurologists, neurosurgeons, psychiatrists, neuro-
otologists, and general practitioners), prescription 
medication use, hospitalizations, surgical interventions, 
and diagnostic testing (CT scans, MRI, cerebral spinal 
fluid (CSF) testing, enzyme-linked immunosorbent assays 
(ELISA), enzyme-linked immunoelectrotransfer blot 
(EITB), biopsies, electroencephalograms (EEG), and 
neurological examinations) performed before, during, 
and after hospitalization were obtained using the forms 
described above. Initial visits to the INNN prior to the first 
NCC-associated hospitalization were included in the pre-
hospitalization cost estimation. Healthcare services received 
at the INNN between two hospitalizations contributed to 
post-hospitalization costs for patients hospitalized more 
than once. 
The cost of physician’s office visits, diagnostic tests, 
a one-day stay in the hospital, and surgery were obtained 
from the year 2006 price list for healthcare services at 
the INNN19. The year 2006 tariffs were used due to their 
availability to the research personnel and to be in line with 
previous studies looking at NCC-related costs in Mexico9. 
Services for all patients included in the study were estimated 
in 2006 U.S. dollars (US$) regardless of the date of 
hospitalization. The prices used in this study are considered 
applicable to other healthcare facilities in Mexico. There 
are seven levels of payments at the INNN, where patients 
pay medical fees according to their household income. 
Patients with a very low household income (level 0) do not 
pay anything, and all costs associated with treatment are 
paid by the healthcare provider (HCP). Level 1-6 patients 
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pay increasing amounts for procedures and services. Based 
on discussions with the hospital personnel, level 5 best 
represents the true cost to the healthcare system. 
In order to estimate the costs associated with prescribed 
medications, a list of drugs along with their dosages were 
extracted from the medical records. Brand name drugs were 
noted if specifically stated in the medical record. Otherwise, 
the active ingredient was recorded. Medication costs were 
obtained from pharmacies in Mexico City, Mexico. When 
only the active ingredient was available, pharmacy costs 
could represent either a brand name or generic drug. In 
situations where more than one dosage was available, 
the dosage that best matched the dosage and formulation 
presented in the medical record was used. A list of the drugs’ 
active ingredients, dosages, and year 2006 pharmacy prices 
is included as supplementary material (Annex 1). Some of 
these combinations are known to represent specific brands, 
while others may represent generic drugs. All patients seen 
at the INNN paid for their medications themselves. A list 
of surgical procedures and their associated costs is also 
included as supplementary material (Annex 2). An exchange 
rate for the year 2006 of 10.80 Mexican pesos to 1 U.S. 
dollar was used20. 
Statistical analysis
Pre-hospitalization, hospitalization, and post-
hospitalization costs were determined for each patient, 
with the average cost per period calculated for all patients. 
Pre-hospitalization costs were obtained by adding the 
actual (level 5) costs associated with office visits to a 
physician, diagnostic testing, and pharmacy costs for 
prescription medications prior to the first hospitalization. 
Similarly, hospitalization costs were obtained by adding 
actual (level 5) costs associated with diagnostic testing 
performed during hospitalization, a hospital stay in a 
private or general ward, surgery, and pharmacy costs for 
prescription medications received during hospitalization. 
An individual patient’s per day hospitalization cost was 
obtained by dividing the patient’s total hospitalization cost 
by the number of hospitalization days. These costs were 
then averaged over the entire study population to obtain 
a mean per day hospitalization cost. Post-hospitalization 
costs were calculated by adding the actual (level 5) costs 
associated with office visits to a physician, diagnostic 
testing, and pharmacy costs for prescription medications 
received after the first hospitalization for NCC at the 
INNN.
Enrolled patients began receiving treatment for NCC 
at the INNN on various dates between 2002 and 2007. 
Therefore, at the beginning of the study, patients had been 
followed for differing lengths of time. Annual costs were 
assessed for up to five years post-hospitalization based on 
the date of treatment initiation at the INNN. Only patients 
followed for at least 12 months after hospitalization were 
included in any post-hospitalization costs estimates. For 
patients with more than one recorded hospitalization, 
post-hospitalization out-patient costs were assessed from 
the date of the first hospitalization for NCC until the date 
of data collection.
Average per-patient level 5 costs were calculated for the 
entire study population as well as stratified by presenting 
clinical manifestation(s). The average costs that the patients 
paid during the pre-hospitalization, hospitalization, and 
post-hospitalization periods were also obtained using the 
payment levels and prescription medication costs. The 
average per-patient cost for each clinical manifestation 
grouping was then compared across the pre-hospitalization, 
hospitalization, and post-hospitalization periods using 
a repeated measures ANOVA, with post hoc pairwise 
comparisons made using Tukey's method. The above 
comparisons were made for all patients followed at least 
one year post-hospitalization. For patients followed at least 
3 years post-hospitalization, the average treatment costs 
for the first, second, and third years post-hospitalization 
were compared using a repeated measures ANOVA, 
with post hoc pairwise comparisons conducted using the 
Tukey method. A t-test was used to compare the average 
per-patient hospitalization cost for patients who had a 
history of surgery with those who did not receive surgery. 
As the number of observations was small after stratifying the 
patients based on clinical manifestation(s), variances of the 
cost estimates were calculated using bootstrap techniques. 
The obtained variances were then used to calculate the 
95% confidence intervals (95% CIs) for the average annual 
costs. All calculations were performed using Stata (Stata 
Statistical Software: Release 11.2. College Station, TX: 
StataCorp LP). A p-value <0.05 was considered statistically 
significant. 
Ethical approval
This study received IRB approval from the Texas A&M 
University (2006-0606 and 2014-0702) and the INNN.
RESULTS
Patient demographics
Among the 163 outpatients recruited, 108 had been 
hospitalized between 2002 and 2007 and 18 of these 
patients were hospitalized more than once. Patients were 
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primarily from the State of Mexico (41%) and Mexico City 
(25%). The demographic characteristics of the hospitalized 
patients are shown in Table 1. The median age at the time 
of first hospitalization for NCC at the INNN was 42 years 
old and ranged from 19 to 84 years old. Almost half of 
the hospitalized patients were male (48%). The number 
of hospitalized days ranged from 2 to 56 per patient. The 
lengths of time the patients were treated at the INNN pre-
hospitalization and post-hospitalization ranged from 0 
days to 5 years and 1 month to 5 years, respectively. Fifty 
percent of patients paid at level 2, with no patients assigned 
to level 0 (Table 1).
Clinical manifestations
The most common clinical manifestations reported were 
severe chronic headaches (21%), hydrocephalus (19%), 
and the combination of hydrocephalus and severe chronic 
headaches (29%) (Figure 1). 
Table 1 - Demographic features of the 108 NCC patients hospitalized at the INNN from 2002 to 2007
Category Level 1 (n=37)
Level 2 
(n=54)
Level 3 
(n=9)
Level 4 
(n=1)
Level 5 
(n=3)
Level 6 
(n=4)
Total 
(n=108)
Number of patients who were hospitalized 
more than once 9 8 0 0 0 1 18
Number of patients who did not receive pre-
hospitalization treatment at the INNN 16 11 4 0 1 1 33
Number of patients who received 1 to 30 days 
of pre-hospitalization treatment at the INNN 10 22 2 0 1 1 36
Number of patients who received 31 to 180 
days of pre-hospitalization treatment at the 
INNN
5 7 2 1 0 0 15
Number of patients who received 181 to 
365 days of pre-hospitalization treatment 
at the INNN
2 2 0 0 1 0 5
Number of patients who received 1 to 2 years 
of pre-hospitalization treatment at the INNN 1 3 1 0 0 1 6
Number of patients who received more 
than 2 years, but less than 3 years of pre-
hospitalization treatment the INNN
1 3 0 0 0 1 5
Number of patients who received more 
than 3 years, but less than 4 years of pre-
hospitalization treatment at the INNN
1 2 0 0 0 0 3
Number of patients who received more 
than 4 years, but less than 5 years of pre-
hospitalization treatment at the INNN
1 4 0 0 0 0 5
Number of patients with records available for 
at least 1 year post-hospitalization 31 43 7 1 2 2 86
Number of patients with records available for 
at least 2 years post-hospitalization 19 25 7 1 2 1 55
Number of patients with records available for 
at least 3 years post-hospitalization 14 17 7 0 2 1 41
Number of patients with records available for 
at least 4 years post-hospitalization 8 12 5 0 1 0 26
Number of patients with records available for 
5 years post-hospitalization 4 7 4 0 0 0 15
* Note: No patient paid at level 0.
Figure 1 - NCC-related clinical manifestations of study patients. 
E/S = Epilepsy/seizures, H = Hydrocephalus, SCH= Severe 
chronic headaches, ST= Stroke, D = Dementia
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Estimation of pre-hospitalization, hospitalization, and 
post-hospitalization costs
Hospitalization costs were significantly higher compared 
to the costs incurred during the pre-hospitalization or 
complete post-hospitalization periods for all clinical 
manifestations except for epilepsy and stroke (Table 2).
Pre-hospitalization costs
The average actual (level 5) per-patient pre-
hospitalization cost was US$ 257 (95% CI: 185 – 329). 
Diagnostic testing made up 81% of this cost, followed 
by office visits to a physician (10%) and prescription 
medications (9%). The average pre-hospitalization cost 
paid for by the patients  was US$ 62 (95% CI: 32 – 92). 
Table 3 shows the average per-patient pre-hospitalization 
costs by presenting clinical manifestation(s). No significant 
difference was found in the per-patient pre-hospitalization 
costs for the various clinical manifestation(s) (p=0.75). 
Overall, thirty-one percent of patients did not receive 
pre-hospitalization treatment. Since few patients received 
pre-hospitalization treatment for more than 30 days, 
stratification by the duration of pre-hospitalization care 
was not conducted.
Hospitalization costs
The average actual (level 5) per-patient hospitalization 
cost was US$ 2,576 (95% CI: 2,244 – 2,908), with an 
average per-patient per-day hospitalization cost of US$ 
269 (95% CI: 218 – 320). The average total hospitalization 
cost paid for by the patients was US$ 424 (95% CI: 
247 – 602), with an average daily cost of US$ 67 (95% 
CI: 6 – 128) (Table 4). Figure 2 shows the average per-
patient per-day hospitalization cost by presenting clinical 
manifestation(s). No significant difference was found 
in the per-patient hospitalization costs for the various 
presenting clinical manifestation(s) (p=0.13). However, 
the cost of hospitalization was significantly higher in 
patients who had surgery (n=66) (US$ 3,487) compared 
to those who did not have surgery (n=42) (US$ 1,166) 
(p<0.001). While 67% of NCC patients with clinical 
manifestations other than epilepsy underwent surgical 
procedures during hospitalization, only 23% of epilepsy 
patients had surgery.
Table 2 - Comparison of average pre-hospitalization, hospitalization, and total post-hospitalization costs for NCC patients treated 
at the INNN between 2002 and 2006 (2006 US$) by clinical manifestation(s)
Clinical Manifestation(s) Pre-hospitalization Hospitalization Post-hospitalization p-value Overall p-value
Epilepsy/seizures (n=11)
191 1,397 0.00 0.00
191 1,258 0.00
1,397 1,258 0.88
Hydrocephalus (n=16)
155 1,983 0.00 0.00
155 663 0.06
1,983 663 0.00
Severe chronic headaches 
(n=21)
306 2,089 0.00 0.00
306 806 0.18
2,089 806 0.00
Stroke (n=2)
269 4,007 0.38 0.36
269 1,054 0.94
4,007 1,054 0.51
Epilepsy/seizures and severe 
chronic headaches (n=6)
448 3,050 0.00 0.02
448 872 0.7
3,050 872 0.01
Epilepsy/seizures and 
hydrocephalus (n=4)
119 4,544 0.00 0.04
119 711 0.85
4,544 711 0.01
Severe chronic headaches 
and hydrocephalus (n=22)
290 3,022 0.00 0.00
290 769 0.28
3,022 769 0.00
Epilepsy/seizures, severe 
chronic headaches, and 
hydrocephalus (n=4)
213 3,488 0.00 0.03
213 539 0.94
3,488 539 0.00
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Table 3 - Average actual (level 5) per-patient pre-hospitalization costs (2006 US$) for NCC patients treated at the INNN between 
2002 and 2006 by clinical manifestation(s) (values in brackets represent 95% CI)
Clinical manifestation(s) Number of patients
Per-patient pre-hospitalization costs (95% CI)
Diagnostic 
tests 
Physician office 
visits
Prescription 
medications Total 
Epilepsy/seizures 13 156 (10 - 303)
12 
(0 - 32)
28 
(4 - 52)
196 
(8 – 402)
Hydrocephalus 21 134 (44 -226) 
10 
(1 – 19)
7 
(2 – 12)
152 
(58 – 246)
Severe chronic headaches 23 239 (75 - 403)
24 
(4 – 44)
24 
(0 – 64)
287 
(106 – 470)
Stroke 2 269 (181 – 356) 0 0
269 
(181 – 356)
Dementia 1 0 60 0 60
Severe chronic headaches and 
hydrocephalus 31
270 
(143 – 397)
49 
(13 – 84)
12 
(0 – 26)
331 
(166 –495)
Epilepsy/seizures and hydrocephalus 4 108 (10 – 207)
5 
(0 – 10)
6 
(0 – 13)
119 
(15 – 223)
Epilepsy/seizures and severe chronic 
headaches 6
263 
(0 – 528)
46 
(0 – 112)
139 
(0 – 334)
448 
(0 – 938)
Epilepsy/seizures, severe chronic 
headaches, and hydrocephalus 7
183 
(51 – 316)
17 
(0 – 42) 0
200 
(43 – 355)
Overall 108 210 (152 – 270)
26 
(15 – 39)
21 
(3 – 40)
257 
(185 – 329)
Table 4 - Average actual (level 5) per-patient hospitalization costs (2006 US$) for NCC patients treated at the INNN between 2002 
and 2006 by clinical manifestation(s) (values in brackets represent 95% CI)
Clinical manifestation(s)
Number 
of patients 
(Number of 
hospitalizations)
Per-patient hospitalization costs (95% CI)
Diagnostic 
tests Hospital stay Surgery 
Prescription 
medications
Total 
hospitalization 
Epilepsy/seizures 13(13) 177 (100 - 253)
1,026 
(655 – 1,397) 
429 
(5 - 853)
107 
(0 – 220)
1,739 
(926 – 2,552)
Hydrocephalus 21 (24) 186 (99 – 273)
803 
(570 – 1,037)
1561 
(947 – 2,176)
13 
(2 –24)
2,565 
(1,787 – 3,342)
Severe chronic headaches 23 (25) 297 (198 – 396)
758 
(585 – 930)
882 
(382 – 1,382)
24 
(7 – 42)
1,961 
(1,427 – 2,496)
Stroke 2 (2) 229 (31 – 427)
2,416 
(441 – 4,393)
1,278 
(90 – 2,468)
82 
(11 – 154)
4,007 
(467 – 7,548)
Dementia 1 (1) 469 748 0 99 1,316
Severe chronic headaches 
and hydrocephalus 31(44)
197 
(115 – 280)
874 
(664 –1,084)
1,782 
(1,245 – 2,318)
28 
(10 – 47)
2,882 
(2,265 – 3,499)
Epilepsy/seizures and 
hydrocephalus 4 (9)
481 
(154 – 809)
1,276 
(680 – 1,872)
2,771 
(1,289 – 4,253)
14 
(0 -33)
4,544 
(2,241 – 6,847
Epilepsy/seizures and 
severe chronic headaches 6 (10)
433 
(115 – 749)
1,316 
(869 – 1,763)
1,279 
(447 – 2,110)
22 
(9 – 35)
3,050 
(1,803 – 4,296)
Epilepsy/seizures, severe 
chronic headaches, and 
hydrocephalus
7 (12) 472 (310 – 634)
904 
(531 – 1,277)
1,819 
(451 – 3,187)
38 
(24 – 52)
3,223 
(1,866 – 4,579)
Overall 108 (140) 254 (206 – 302)
922 
(689 – 1,155)
1,365 
(797 – 1,933)
35 
(19 – 51)
2,576 
(2,244 – 2,908)
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Post-hospitalization costs
The average actual (level 5) per-patient costs for one 
to five years post-hospitalization were US$ 475 (95% 
CI: 423 – 527), US$ 228 (95% CI: 167 – 288), US$ 157 
(95% CI: 111 – 202), US$ 150 (95% CI: 106 – 204), 
and US$ 91 (95% CI: 27 – 154), respectively (Table 5 
and Figure 2). For patients followed up for at least 3 
years post-hospitalization (n=41), the average cost for 
the first post-hospitalization treatment year (US$ 445) 
was significantly higher than that for the second year 
post-hospitalization (US$ 316) (p=0.05), which in turn 
was not significantly higher than that for the third year 
post-hospitalization (US$ 239) (p=0.35). No significant 
difference was found in the per-patient costs for the various 
clinical manifestation(s) for the post-hospitalization period 
(p=0.37) (Table 5). Figure 3 shows the average post-
hospitalization costs broken down by the cost components 
of diagnostic testing, visits to a healthcare provider, and 
prescription medications. The costs paid for by the patients 
for one to five years post-hospitalization were US$ 114 
(95% CI: 88 – 141), US$ 56 (95% CI: 32 – 80), US$ 47 
(95% CI: 25 – 69), US$ 45 (95% CI: 17 – 74), and US$ 32 
(95% CI: 0 – 66), respectively. Most of these costs were 
due to prescription medications (Figure 4). 
DISCUSSION
This is the first patient-based study estimating the 
direct monetary expenses associated with NCC-affected 
individuals in Mexico during the pre-hospitalization, 
hospitalization, and post-hospitalization periods. Overall, 
substantial costs were associated with patients requiring 
hospitalization for NCC, with this burden continuing 
years post-hospitalization. When all patients, regardless of 
Figure 2 - Average actual (level 5) per-patient per-day 
hospitalization costs (US$) for NCC patients treated at the 
INNN by clinical manifestation(s) (The plot whiskers extend to 
the upper and lower 95% confidence intervals). E/S = Epilepsy/ 
seizures, H = Hydrocephalus, SCH= Severe chronic headaches, 
ST= Stroke, D = Dementia
Table 5 - Average actual (level 5) per-patient post-hospitalization costs (2006 US$) for NCC patients treated at the INNN between 
2002 and 2006 by clinical manifestation(s) (values in brackets represent 95% CI)
Clinical manifestations
Per-patient post-hospitalization costs (95% CI), 
(number of patients)
1st year 2nd year 3rd year 4th year 5th year
Epilepsy/ seizures 648 (421 - 874) (n=11)
319 (66 – 574) 
(n=9)
220 (65 – 376) 
(n=6)
207 (44 – 398) 
(n=4)
197 
 (n=1)
Hydrocephalus 480 (369 – 591) (n=16)
115 (51 – 180) 
(n=9)
187(54 – 320) 
(n=4)
159 (23 – 295) 
(n=3)
127 (5 – 245) 
(n=2)
Severe chronic headaches 474 (357 – 592) (n=21)
302 (173 – 432) 
(n=11)
176 (78 – 275) 
(n=8)
226 (99 – 353) 
(n=5)
151 (1 – 301) 
(n=4)
Stroke 506 (255 – 665) (n=2)
105 (0 – 218) 
(n=2)
238 
(n=1)
304 
(n=1)
209 
(n=1)
Dementia* - - - - -
Severe chronic headaches and 
hydrocephalus
461 (379 – 542) 
(n=22)
244 (136 – 352) 
(n=15)
145 (84 – 206) 
(n=13)
67 (16 – 118) 
(n=10)
20 (1 – 38) 
(n=6)
Epilepsy/seizures and 
hydrocephalus
450 (328 – 571) 
(n=4)
167 (46 – 291) 
(n=3)
134 (0 – 291) 
(n=2)
124 (0 – 275) 
(n=2)
20 
 (n=1)
Epilepsy/seizures and severe 
chronic headaches
376 (221 – 531) 
(n=6)
266 (46 – 487) 
(n=4)
114 (0 – 246) 
(n=4)
215 
(n=1) -
Epilepsy/seizures, severe chronic 
headaches, and hydrocephalus
373 (161 – 585) 
(n=4)
122 (31 – 213) 
(n=2) - - -
Overall 475 (423 – 527) (n=86)
228 (167 – 288) 
(n=55)
157 (111 – 202) 
(n=41)
150 (106 – 204) 
(n=26)
91 (27 – 154) 
(n=15)
* The dementia patient was followed for less than 12 months and was, therefore, not included in the estimation of post-hospitalization 
costs
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having received pre-hospitalization care at the INNN, were 
included in the analysis, the direct economic expenses pre-
hospitalization, during hospitalization, and during the first 
year post-hospitalization were equivalent to 22%, 224%, 
and 42% of an annual minimum wage salary in Mexico 
(US$ 1,145), respectively21. Overall, pre-hospitalization 
represented the least expensive cost period for patients. 
However, pre-hospitalization costs increased from 22% to 
32% of an annual minimum wage salary when only those 
patients with pre-hospitalization treatment were included21.
Very few studies have been conducted to estimate the 
cost associated with NCC patients. In the current study, 
patients incurred expenses equivalent to 64% of an annual 
minimum wage salary during the pre-hospitalization period 
plus one year post-hospitalization21. In comparison, non-
hospitalized Indian patients with NCC-associated epilepsy 
were shown to spend 51% of their per capita gross national 
product (GNP) on direct and indirect costs associated with 
their disease during their treatment period, which ranged 
from 1 to 14 months14. Unfortunately, direct comparison 
between these two studies is difficult. Not only did the 
Indian study use per capita GNP versus wage data, this 
study also restricted participants to only those NCC patients 
with epilepsy. Since the cost of prescription medications 
tends to be higher for epileptic patients with NCC compared 
to non-epileptic NCC patients, it would be expected that 
epileptics would incur higher costs. In our study, epileptic 
patients were spending twice as much on prescription 
medications compared to non-epileptic patients. If we 
consider only the epileptic patients in our study, economic 
expenses were equivalent to 72% of an annual minimum 
wage salary during pre-hospitalization plus the first year 
post-hospitalization. Another reason why these two studies 
are difficult to compare is that the Indian study also included 
indirect expenses whereas the current Mexican study did 
not. Productivity losses accounted for 17% of total costs 
associated with the Indian patients. 
In another study conducted in a reference hospital in 
Peru, NCC patients were spending 54% and 16% of an 
annual minimum wage salary on direct and indirect costs 
associated with their disease during their first year and 
second year of treatment, respectively13. This study included 
patients with and without epilepsy as well as hospitalized 
and non-hospitalized patients whereas the current study only 
included hospitalized patients. Overall, 78% of the patients 
in the Peruvian study were hospitalized. The Peruvian 
patients spent a smaller proportion of a minimum wage 
salary on treatment costs compared to the Mexican patients. 
One possible reason for this difference is that 61% of the 
patients in the current study underwent surgery whereas 
none of the Peruvian patients underwent surgery. The pre-
hospitalization, hospitalization, and post-hospitalization 
costs for the Mexican patients who did not have surgery 
were 16%, 100% and 66% of an annual minimum wage 
salary, respectively. Hospitalization and post-hospitalization 
values were, therefore, about 50% lower than for the entire 
studied population. It should be noted that the Peruvian 
study also included productivity losses, which were not 
assessed in the current Mexican study. Productivity losses 
accounted for 10% of total costs in the Peruvian study. 
In the current study, the hospitalization period incurred 
higher per-patient costs for all clinical manifestations 
when compared to the pre-hospitalization or entire 
post-hospitalization period. However, this cost was not 
significantly higher for patients with epilepsy or stroke as 
the sole presenting clinical manifestation. In comparison 
to patients with other clinical manifestations, fewer 
epilepsy cases had surgery and the number of patients with 
stroke was very small, explaining the lack of significant 
differences for these two groups. The post-hospitalization 
costs were highest in the first year post-hospitalization, 
which was likely due to the greater number of diagnostic 
Figure 4 - Average costs paid by the patients, broken down by 
cost component and year of treatment post-hospitalization for 
NCC patients treated at the INNN. Note: There were 86, 55, 
41, 26, and 15 patients who received treatment one, two, three, 
four, and five years post-hospitalization, respectively
Figure 3 - Average costs broken down by cost component and 
year of treatment post-hospitalization for NCC patients treated 
at the INNN. Note: There were 86, 55, 41, 26, and 15 patients 
who received treatment one, two, three, four, and five years 
post-hospitalization, respectively
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tests performed in this year as compared to subsequent 
years. The average number of hospitalized days for patients 
whose records were evaluated after they had received only 
one year of treatment post-hospitalization (11 days) was 
similar to patients whose records were evaluated after 
they had received more than one year of treatment post-
hospitalization (13 days). Therefore, the patient’s clinical 
severity at the time of hospitalization did not greatly 
influence these values. 
Although our results suggest that the actual cost to treat 
NCC is high compared to an annual minimum wage salary 
in Mexico, most patients in this study paid a reduced amount 
based on their income. The exception was for prescription 
medications. The vast majority (83%) of patients paid 
at level 2 or below, which is well below the actual costs 
to the healthcare system, indicating that they fell into 
a lower income bracket. Although they paid a reduced 
amount compared to the actual price of services, they 
were still spending a considerable proportion of an annual 
minimum wage salary during the pre-hospitalization and 
hospitalization periods combined (43%), and during the first 
year post-hospitalization (10%). It should be noted that costs 
associated with treatment that were not paid by patients 
were absorbed by the hospital system and, therefore, by 
the society as a whole.
This study has some limitations. Data were collected 
from medical chart reviews, which limited the assessed 
variables to those recorded as part of the standard medical 
charting process and those anticipated to be of value 
prior to the beginning of this study. Therefore, type 
of NCC (intraparenchymal versus extraparenchymal), 
cyst viability, and actual wage data were not available 
for analysis. Our estimates are also an underestimate 
of the total costs associated with NCC among patients 
hospitalized at the INNN since indirect costs such as loss 
of working days due to visits to a healthcare provider 
or during hospitalization, cost of over-the-counter 
medication, cost of traditional medicine/treatment, 
reduction in productivity level, costs associated with 
transportation to and from medical treatment, and time 
lost by the patient’s family to take care of them or to 
accompany them to treatment were not available for 
analysis22. In addition, this information excludes any 
costs incurred while receiving treatment in a healthcare 
facility other than the INNN, which could especially 
affect the estimated pre- and post-hospitalization costs. 
Finally, this study was conducted in a neurology reference 
hospital, which likely sees many of the more severe cases. 
Therefore, the determined costs cannot be extrapolated to 
all NCC cases in Mexico. 
While the actual costs associated with healthcare 
services may change over time, the relative proportion of 
costs associated with the pre-hospitalization, hospitalization 
and post-hospitalization periods will likely remain more 
stable. Therefore, values presented in this study can be used 
by Mexico to better define the direct costs associated with 
NCC patients who are hospitalized at tertiary care hospitals, 
with the ultimate goal of better conveying the true economic 
impact of NCC to policy makers. 
ACKNOWLEDGMENTS
We would like to thank all of the people involved in the 
collection of data in Mexico.
FINANCIAL SUPPORT
This work was funded by the Texas A&M University-
CONACYT Collaborative Research Grant Program. The 
open access publishing fees for this article have been 
covered by the Texas A&M University Open Access to 
Knowledge Fund (OAKFund), supported by the University 
Libraries and the Office of the Vice President for Research.
REFERENCES
 1. Rajshekhar V, Joshi DD, Doanh NQ van De N, Xiaonong Z. Taenia 
solium taeniosis/cysticercosis in Asia: epidemiology, impact 
and issues. Acta Trop. 2003;87:53-60. 
 2. Zoli A, Shey-Njila O, Assana E, Nguekam JP, Dorny P, Brandt 
J, et al. Regional status, epidemiology and impact of Taenia 
solium cysticercosis in Western and Central Africa. Acta Trop. 
2003;87:35-42. 
 3. Flisser A, Sarti E, Lightowlers M, Schantz P. Neurocysticercosis: 
regional status, epidemiology, impact and control measures in 
the Americas. Acta Trop. 2003;87:43-51. 
 4. O’Keefe KA, Eberhard ML, Shafir SC, Wilkins P, Ash LR, 
Sorvillo FJ. Cysticercosis-related hospitalizations in the United 
States, 1998-2011. Am J Trop Med Hyg. 2015;92:354-9. 
 5. Del Brutto OH. A review of cases of human cysticercosis in 
Canada. Can J Neurol Sci. 2012;39:319-22. 
 6. Bruno E, Bartoloni A, Zammarchi L, Strohmeyer M, Bartalesi 
F, Bustos JA, et al. Epilepsy and neurocysticercosis in Latin 
America: a systematic review and meta-analysis. PLoS Negl 
Trop Dis. 2013;7:e2480. 
 7. Bhattarai R, Budke CM, Carabin H, Proaño JV, Flores-Rivera 
J, Corona T, et al. Estimating the non-monetary burden 
of neurocysticercosis in Mexico. PLoS Negl Trop Dis. 
2012;6:e1521. 
 8. Bhattarai R, Budke CM, Carabin H, Proaño JV, Flores-Rivera J, 
Corona T, et al. Quality of life in patients with neurocysticercosis 
in Mexico. Am J Trop Med Hyg. 2011;84:782-6. 
Bhattarai et al.
Rev Inst Med Trop São Paulo. 2018;60:e20Page 10 of 11
 9. Bhattarai R, Carabin H, Proaño JV, Flores-Rivera J, Corona T, 
Flisser A, et al. Cost of neurocysticercosis patients treated in 
two referral hospitals in Mexico City, Mexico. Trop Med Int 
Health. 2015;20:1108-19. 
 10. Carabin H, Krecek RC, Cowan LD, Michael L, Foyaca-Sibat 
H, Nash T, et al. Estimation of the cost of Taenia solium 
cysticercosis in Eastern Cape Province, South Africa. Trop 
Med Int Health. 2006;11:906-16. 
 11. Praet N, Speybroeck N, Manzanedo R, Berkvens D, Nsame 
Nforninwe D, Zoli A, et al. The disease burden of Taenia solium 
cysticercosis in Cameroon. PLoS Negl Trop Dis. 2009;3:e406. 
 12. Wallin MT, Pretell EJ, Bustos JA, Caballero M, Alfaro M, 
Kane R, et al. Cognitive changes and quality of life in 
neurocysticercosis: a longitudinal study. PLoS Negl Trop Dis. 
2012;6:e1493. 
 13. Rajkotia Y, Lescano AG, Gilman RH, Cornejo C, Garcia HH. 
Economic burden of neurocysticercosis: results from Peru. 
Trans R Soc Trop Med Hyg. 2007;101:840-6. 
 14. Murthy JM, Rajshekar G. Economic evaluation of seizures 
associated with solitary cysticercus granuloma. Neurol India. 
2007;55:42-5. 
 15. Croker C, Reporter R, Mascola L. Use of statewide hospital 
discharge data to evaluate the economic burden of 
neurocysticercosis in Los Angeles County (1991-2008). Am 
J Trop Med Hyg. 2010;83:106-10. 
 16. O’Neal SE, Flecker RH. Hospitalization frequency and charges 
for neurocysticercosis, United States, 2003-2012. Emerg Infect 
Dis. 2015;21:969-76. 
 17. Fica A, Weitzel T. Gastos hospitalarios en pacientes con 
fascioliasis en fase aguda, hidatidosis de tratamiento quirúrgico 
y neurocisticercosis en un hospital general en Chile. Rev 
Chilena Infectol. 2014;31:406-10. 
 18. Del Brutto OH, Rajshekhar V, White AC Jr, Tsang VC, Nash 
TE, Takayanagui OM, et al. Proposed diagnostic criteria for 
neurocysticercosis. Neurology. 2001;57:177-83. 
 19. México. Secretaría de Finanzas. Subsecretaría de Ingresos, 
Unidade de Política de Ingresos. Tabulador de cuotas de 
recuperación: Instituto Nacional de Neurología y Neurocirugía 
Manuel Velasco Suaréz. México: Secretaria de Finanzas; 2006.
 20. OANDA Solutions for Business. Historical rates. [cited 2018 
March 7]. Available from: https://www.oanda.com/fx-for-
business/historical-rates 
 21.  México. Secretaría del Trabajo y Previsión Social. Salarios 
mínimos vigentes a partir de 1º de enero de 2006. [cited 2018 
March 7]. Available from: http://www.conasami.gob.mx/pdf/
tabla_salarios_minimos/2006/01_01_31_12_2006.pdf 
 22.  Bhattarai R, Carabin H, Budke CM. The burden of cysticercosis. 
In: Sibat HF, editor. Novel aspects on cysticercosis and 
neurocysticercosis. London: InTech; 2013. p.59-76.
Rev Inst Med Trop São Paulo. 2018;60:e20
Pre-hospitalization, hospitalization and post-hospitalization costs of patients with neurocysticercosis
Page 11 of 11
Annex 1 - List of drugs prescribed for NCC patients treated at 
the INNN between 2002 and 2006
 
Drug Name Dosage Pharmacy price in US$
Acetaminophen 500 mg 0.08
Acetylsalicylic acid 100 mg 0.07
Albendazole 200 mg 0.69
Captopril 25 mg 0.02
Carbamazepine 200 mg 0.08
Cinnarizine 75 mg 0.83
Ciprofloxacin 500 mg 0.35
Clobazam 10 mg 0.46
Clonazepam 2.5 mg 0.04
Clonixin lysine-cyclobenzapine 100 mg/2 ml 0.5
Dexamethasone 8 mg/2 ml 0.27
Enalapril 10 mg 0.23
Fluoxetine 20 mg 2.4
Galantamine 4 mg 1.27
Ibuprofen 400 mg 0.75
Ketorolac 10/30 mg 0.12
Lamotrigine 100 mg 1.41
Metoclopramide 10 mg 0.03
Metronidazol 500 mg 0.19
Nimodipine 30 mg 0.96
Omeprazole 20/40 mg 0.04/3.50
Phenytoin 100/250 mg 0.16/1.40
Praziquantel 600 mg 5.86
Prednisone 5mg/50 mg 0.02/0.10
Primidone 250 mg 0.16
Propanolol 40 mg 0.13
Quetiapine 25 mg 0.77
Ranitidine 150/300 mg 0.10/0.15
Topiramate 100 mg 1.93
Valproic acid 200 mg 0.11
Vigabatrin 300 mg 0.53
Annex 2 - List of surgical procedures performed on NCC 
patients treated at the INNN between 2002 and 2006 
Type of Surgery Level 5 Cost in US$
Close up ventriculostomy 71
Craniotomy 2,389
Cysticercosis removal/resection 1,535
Endoscopic exploration 307
Laminectomy 2,507
Replacement/removal of vericulo-peritoneal 
shunt
1,023
Valve replacement 1,023
Valvular dysfunction 1,023
Ventriculoperitoneal shunt placement 1,535
Ventriculostomy 511
